GlassScriptPhysician profile
Nabil K Abudayeh
NPI 1699724484
$7,938.55
in general payments reported to CMS, 2019-2025
35 companies · $969 in 2025
The $969 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,771 · 2020: $671 · 2021: $1,315 · 2022: $1,039 · 2023: $1,208 · 2024: $967 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102 · Education: $41.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.90 |
| Education | $41.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,146.39 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $1,111.55 | 2019 | |
| Novo Nordisk INC | $827.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $765.66 | 2019-2023 | Xarelto |
| Amgen INC. | $664.81 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $496.08 | 2022-2025 | |
| Pfizer INC. | $492.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $310.09 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $253.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $237.82 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $211.58 | 2019-2022 | |
| Lilly USA, LLC | $185.05 | 2020-2025 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $164.94 | 2023-2025 | Camzyos, Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $155.29 | 2022 | |
| Amarin Pharma, INC. | $113.46 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $92.82 | 2021 | |
| Abbott Laboratories | $78.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $76.74 | 2019-2020 | |
| Baxter Healthcare | $72.03 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.92 | 2021-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $52.77 | 2021-2022 | |
| Exact Sciences Corporation | $45.07 | 2024-2025 | Cologuard Collection Kit |
| Ionis Pharmaceuticals, INC. | $36.68 | 2025 | Tryngolza |
| Genzyme Corporation | $32.65 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $28.88 | 2021 | |
| Becton, Dickinson and Company | $27.52 | 2024 | Venclose Maven Catheter |
| Medtronic, INC. | $26.46 | 2021 | |
| Irhythm Technologies, INC. | $24.56 | 2020-2022 | |
| Seqirus USA INC | $23.77 | 2025 | Fluad, Flucelvax |
| Edwards Lifesciences Corporation | $23.60 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Allergan, INC. | $23.41 | 2019 | |
| Atricure, INC. | $22.64 | 2022 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.08 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.83 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Abudayeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.